Revenue segments as reported by the company.

Consumer Health

Pharmaceutical

Medical Devices

Innovative Medicine

MedTech

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, marketing and administrative expenses

Research and development expense

In-process research and development

Interest expense

Other expense

Restructuring

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Johnson & Johnson

Band-Aid is a brand name of American pharmaceutical and medical devices giant Johnson & Johnson's line of adhesive bandages.

Band-Aid

Johnson's Baby is an American brand of baby cosmetics and skin care products owned by Johnson & Johnson. The brand dates back to 1893 when Johnson's Baby Powder was introduced. Product line consists of baby powder, shampoos, body lotions, massage oil, shower gels and baby wipes. The brand has reputation for making baby products that are "exceptionally pure and safe" since at least the 1980s.

Johnson's Baby

Aveeno is a brand of skin care and hair care products in the United States owned by American consumer goods and pharmaceutical company Johnson & Johnson. Aveeno was founded in 1945, and its first product was their Soothing Bath Treatment. The active ingredient in all Aveeno products are colloidal oats and/or oat extracts - Avenanthramides, which have been branded as "active naturals". Aveeno offers products to treat skin conditions such as eczema, psoriasis, urushiol-induced contact dermatitis, pruritus ani, chickenpox, hives, and sunburn.

Aveeno

Neutrogena is an American brand of skin care, hair care and cosmetics, that is headquartered in Los Angeles, California. According to product advertising at their website, Neutrogena products are distributed in more than 70 countries. Neutrogena was founded in 1930 by Emanuel Stolaroff, and was originally a cosmetics company named Natone. It is now part of the US-based Johnson & Johnson conglomerate, which bought the independent company in 1994.

Neutrogena

Clean & Clear is a line of dermatology products owned by Johnson & Johnson.

Clean & Clear

Listerine is a brand of antiseptic mouthwash product. It is promoted with the slogan "Kills germs that cause bad breath". Named after Joseph Lister, a pioneer of antiseptic surgery, Listerine was developed in 1879 by Joseph Lawrence, a chemist in St. Louis, Missouri.

Listerine

Acuvue (from "Accurate view") is a brand of disposable contact lenses made by Jacksonville-based Vistakon, a subsidiary of Johnson & Johnson (J&J).

Acuvue

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Johnson & Johnson reports solid Q4 earnings, eyes $60B Pharma revenue

Johnson & Johnson's Q4 2022 showed steady operational growth and strong financial performance. The company aims for continued growth in Pharmaceuticals, focusing on key products and pipeline advancements. Challenges include managing costs, addressing sales declines, and navigating market uncertainties.

Johnson & Johnson reports resilient Q1 performance amidst challenges

Johnson & Johnson's Q1 2023 performance reflects resilience and growth across key segments despite short-term challenges.
The company's strategic focus on innovation, resource management, and portfolio diversification positions it for future success.
While facing legal and financial headwinds, Johnson & Johnson remains optimistic about its outlook for 2023 and beyond.
Increased guidance, product developments, and commitment to safety and innovation underscore the company's long-term growth potential.

Johnson & Johnson reports strong Q2 earnings and strategic growth plans

Johnson & Johnson showcased robust financial results in Q2, raising full-year guidance and highlighting growth in MedTech and Pharmaceuticals. Despite challenges from pricing pressures and litigation, the company remains focused on strategic opportunities and maintaining a strong market position. With a clear focus on innovation and growth, Johnson & Johnson is poised for continued success in the healthcare sector.

Johnson & Johnson posts strong Q3 results amidst growth strategies

Johnson & Johnson (JNJ) delivered robust Q3 results, showcasing growth in sales, earnings, and operational efficiency across key segments, positioning the company for future success.
While facing challenges from geopolitical factors, legal issues, and upcoming competition, JNJ's strategic strengths in acquisitions, innovation, and market presence offer avenues for sustained growth.
With a focus on key brands, pipeline advancements, and MedTech innovations, JNJ remains poised to meet revenue targets, navigate challenges, and capitalize on market opportunities in the coming years.

Johnson & Johnson reports robust 2023 performance and strategic growth outlook

Johnson & Johnson's strong 2023 performance in Innovative Medicine and MedTech drove operational sales growth. Despite inflationary pressures impacting margins, JNJ remains focused on enhancing shareholder returns and pursuing strategic M&A deals. Opportunities for growth in 2024 include new product launches and advancements in key focus areas.

Johnson & Johnson posts strong Q1 earnings, eyes growth opportunities

Johnson & Johnson's Q1 2024 earnings reflect solid performance across key segments, with a focus on innovation and strategic growth initiatives.
Despite challenges in certain segments, the company's proactive approach to restructuring and market dynamics positions it for future success.
Opportunities in Vision Care, Pulmonary Hypertension, and Orthopaedics underscore potential for sustained growth and market leadership.
Overall, Johnson & Johnson's diversified product portfolio and financial outlook support confidence in achieving growth targets for 2024.

Johnson & Johnson posts strong Q2 results, eyes growth opportunities

Johnson & Johnson delivered a robust performance in Q2 2024, driven by strong sales growth in both Innovative Medicine and MedTech segments, supported by strategic initiatives.
While facing challenges in certain markets and the need for continued innovation, the company's outlook remains positive with a solid guidance for the full year 2024.
By capitalizing on opportunities in key products and markets, Johnson & Johnson is well-positioned to navigate challenges and drive sustainable growth in the healthcare sector.

Johnson & Johnson reports robust Q3 earnings amidst legal challenges

Johnson & Johnson's Q3 2024 earnings call showcased strong financial performance, driven by growth in key segments and successful product launches. Despite facing challenges with talc litigation, the company remains focused on innovation, capital allocation, and resolving legal issues.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares of Johnson & Johnson took a 1.4% hit in morning trading Friday, after a report that health officials decided the drugmaker needs to throw out millions of doses of its COVID-19 vaccine because of possible contamination. The New York Times reported Friday, citing people familiar with the situation, that after weeks of review, the Food and Drug Administration told J&J to discard 60 million doses of its vaccine made at a Baltimore plant under federal review, which is operated by Emergent BioSolutions Inc. , because of possible contamination.

J&J stock drops after report FDA said millions of COVID-19 vaccine doses need to be discarded

The US government is stopping orders of Johnson & Johnson COVID-19 vaccines so states can try to use up stockpiled doses as vaccination rates drop, the Wall Street Journal reported on Thursday. US state and federal health officials told The Journal that the Centers for Disease Control and Prevention (CDC) is banning states from ordering the J&J shot. Some of the officials said it was only a temporary measure.

The US government is blocking states from ordering Johnson & Johnson's COVID-19 vaccine so they can clear their backlog of unused doses

Verizon

Verizon Communications Inc 5.9 % Notes 2014-15.2.54 Sr

Which classic dividend stock is the more promising investment?

Better Buy: Verizon Communications vs. Johnson & Johnson

Moderna

Pfizer

Teens represent the next big group needing vaccination.

Which Company Will Dominate the Teen Vaccination Market This Fall?

Apple

Costamare

Freeport-McMoRan

McDonald's

Walmart

Here are seven value stocks from fundamentally strong companies that look good for upside and provide investors with dividend income. The post Anti-Meme Stocks: 7 Value Stock Picks for Common Sense Investors appeared first on InvestorPlace.

Anti-Meme Stocks: 7 Value Stock Picks for Common Sense Investors

Dividends are one of the best benefits to being a shareholder, but finding a great dividend stock is no easy task. Does Johnson & Johnson (JNJ) have what it takes?

Are You Looking for a High-Growth Dividend Stock? Johnson & Johnson (JNJ) Could Be a Great Choice

"We could be looking at this tagging along with the flu shot, likely over the next several years," J&J CEO Alex Gorsky said.

J&J CEO says people will need Covid vaccine with annual flu shot for next several years as variants spread

The rollout of Johnson & Johnson Covid-19 vaccine has been off to a rocky start amid concerns of extremely rare but potentially deadly side-effects of blood clots and manufacturing and quality issues at a plant run by a contractor in Baltimore. Demand for the shot has also been tepid in the U.S..

What's Happening With Johnson & Johnson's Covid-19 Vaccine?

NEW BRUNSWICK, N.J., June 9, 2021 /PRNewswire/ -- Johnson & Johnson (NYSE: JNJ) today published the 2020 Health for Humanity Report (Report), which serves as the Company's annual disclosure on environmental, social and governance (ESG) performance and illustrates progress toward fulfilling its corporate purpose to change the trajectory of health for humanity.

Johnson & Johnson Releases 2020 Health for Humanity Report Highlighting Performance and Progress on Environmental, Social and Governance Priorities

Goldman Sachs

Johnson & Johnson's (JNJ) Management Presents at Goldman Sachs 42nd Annual Global Healthcare Conference (Transcript)

AbbVie

Atmos Energy

Becton, Dickinson and Co.

Investors looking for the highest-quality dividend growth stocks to buy and hold for the long term should consider the Dividend Aristocrats, note Ben Reynolds and Bob Ciura, editors at Sure Dividend and contributors to MoneyShow.com.

The Top Dividend Aristocrats To Buy Now

Amid safety concerns about Johnson & Johnson's (NYSE: JNJ) COVID-19 vaccine, along with the weakening of demand for vaccinations, around half of 21 million doses produced for the U.S. is sitting unused, Reuters reported. What Happened: J&J's shot, being a single dose, was supposed to be an essential tool for reaching rural areas and vaccine-hesitant citizens.

Safety Concerns, Lower Demand Interrupts Use of Johnson & Johnson COVID-19 Shot: Reuters

argenx

Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting cusatuzumab. The pair first came together to develop the med across various blood cancers and disorders in December 2018.

Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab

Salesforce

Cisco Systems

Home Depot

Intel

Coca-Cola

Lizhi

Microsoft

NIKE

Newpark Resources

Travelers

UnitedHealth Group

Walgreens

Two new sample breakout stocks for Week 23 with better than 10% short-term upside potential. This past week, the peak gains were in RMO +17.4% and NNDM +10.8% with all 4 picks gaining more than +5% in less than 5 days.

Week 23 MDA Breakout Stocks - June 2021: Short-Term Picks To Give You An Edge

Stryker

Zimmer Biomet Hlds

As hospitals address the major backlog of pandemic-postponed elective surgeries, medical device makers -- and their stock prices -- could benefit.

This Part of the Reopening Trade Is Just Getting Started

Johnson & Johnson (JNJ) CEO Alex Gorsky Presents at Bernstein's 37th Annual Strategic Decisions Virtual Conference (Transcript)

Johnson & Johnson's litigation risks are weighing on its credit profile, according to Moody's Investors Service, citing the news this week that the Supreme Court denied the company's appeal regarding a talc lawsuit and ordered it to pay $2.5 billion to 20 plaintiffs. The payment includes the original $2.1 settlement, plus interest.

Moody's: J&J faces 'litigation exposure' from talc lawsuits, proposed opioid settlement

Shares of Johnson & Johnson rose 0.4% in morning trading, in the wake of the U.S. Supreme Court's denial of the request to review a Missouri court verdict regarding various talc cases against the consumer products and drug maker. As a result of the Supreme Court decision, J&J disclosed in an 8-K filing with the Securities and Exchange Commission late Tuesday that it will make a $2.5 billion payment, including interest, in June.

J&J stock gains after Moody's says $2.5 billion payment for talc claims doesn't affect Aaa rating

The U.S. Supreme Court rejects J&J's (JNJ) appeal against a lower court verdict of $2.1 billion in damages in a litigation related to its talc-based baby powder.

J&J (JNJ) to Pay $2.5B in Baby Powder Case on Appeal Rejection

AstraZeneca

BioNTech SE

Dyadic International Inc., DE

The party is apparently “On” as far as the developed world's sense of “reopening” is concerned. But the global truth is far removed from this celebration, as less than 20% of the world's population have had access to a vaccine.

The Vaccine Investment Hypothesis, and What's Next (AZN, JNJ, DYAI, BNTX)

Apellis Pharma

BridgeBio Pharma Inc

Lantheus Holdings

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive outcomes.

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates

The company has set aside nearly $4 billion as a "litigation expense."

Supreme Court Rules Johnson & Johnson Must Pay $2.1 Billion in Baby Powder Lawsuit

Johnson & Johnson (NYSE: JNJ) will not be getting out of its obligation to pay up for losing a civil court case over its baby powder products that allegedly contained asbestos. On Tuesday, the U.S. Supreme Court announced it would not hear the company's appeal of a $2.1 billion verdict from a 2018 trial in Missouri involving women who argued that the products contributed to their ovarian cancer.

News for Johnson & Johnson Stock (JNJ)